Regulatory authorities have approved 3D skin models as in vitro alternatives to animal testing. The characteristics of 3D tissue models are more relevant to the in vivo situation than 2D models, and as their complexity evolves (e.g., using stem cells and/or co-culture models) these models will become more predictive, serving as a critical tool in toxicological research, according to the company.
Dr. Anthony Baxter, Cyprotex's chief executive officer, said, "Understanding the mechanisms of toxicology of new therapeutics remains a challenging area. Cyprotex is committed to research in this field to help our clients bring safer drugs to the market. By investing in the ArrayScanTM XTI and the Seahorse XFe we are equipped with some of the latest cutting-edge technologies, allowing us to expand our current offerings into key specialist areas.”